Recombinant thyrotropin vs levothyroxinewithdrawal in 131I therapy of N1 thyroid cancer: A large matched cohort study (ThyrNod)

Abstract

Context: Recombinant human thyrotropin (rhTSH) has been shown to be an effective stimulation method for radioactive iodine (RAI) therapy in differentiated thyroid cancer, including in those with nodal metastases (N1 DTC). Objectives: To demonstrate the noninferiority of rhTSH vs thyroid hormone withdrawal (THW) in preparation to RAI regarding disease status at the first evaluation in the real-life setting in patients with N1 DTC. Design: This was a French multicenter retrospective study. Groups were matched according to age (<45/≥45 years), number of N1 nodes (≤5/<5 lymph nodes), and stage (pT1-T2/pT3). Results: The cohort consisted of 404 patients pT1-T3/N1/M0 DTC treated with rhTSH (n = 205) or THW (n = 199). Pathological characteristics and initially administrated RAI activities (3.27 ± 1.00 GBq) were similar between the two groups. At first evaluation (6 to 18 months post-RAI), disease-free status was defined by thyroglobulin levels below threshold and a normal ultrasound. Disease-free rate was not inferior in the rhTSH group (75.1%) compared with the THWgroup (71.9%). The observed difference between the success rates was 3.3% (26.6 to 13.0); rhTSH was therefore considered noninferior to THWbecause the upper limit of this intervalwas,15%. At the last evaluation (29.7±20.7months for rhTSH; 36.7±23.8months for THW), 83.5%(rhTSH) and 81.5%(THW) of patients achieved a complete response. This result was not influenced by any of the known prognostic factors. Conclusions: A preparation for initial RAI treatment with rhTSH was noninferior to that withTHWin our series of pT1-T3/N1/M0-DTC on disease-free status outcomes at the first evaluation and after 3 years.